Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S.

The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant ...

Pharmaceutical giant Eli Lilly alleges the companies are selling off-brand versions of its best-selling diabetes and ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at ...

Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the company and its stock ...

People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...

Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for ...